Founded with a mission to address critical unmet medical needs, Hemoglobin Oxygen Therapeutics LLC is a biotechnology company that develops, manufactures, and commercializes oxygen-carrying solutions. Their core product, Hemopure®, is designed for both human and veterinary applications, providing innovative solutions for oxygen delivery in medical treatments. The company serves a global market, focusing on enhancing patient outcomes in scenarios where traditional blood transfusions are not feasible or available.

Notable achievements include multiple presentations and studies showcasing the efficacy of Hemopure®, such as its pivotal role in donor liver preservation and preclinical results in kidneys discarded for human transplantation. These accomplishments have been highlighted in reputable publications like Nature. Hemoglobin Oxygen Therapeutics has made significant strides in the biotech field, contributing to advancements in medical treatments and improving the quality of life for patients worldwide.